{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:27:36Z","timestamp":1787682456119,"version":"build-2784847793"},"reference-count":15,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Human herpesvirus 8 (HHV\u20108), also known as Kaposi's sarcoma (KS)\u2013associated herpesvirus, is involved in KS and other tumors, including multicentric Castleman's disease and primary effusion lymphoma. Rituximab (RTX) is currently used for the treatment of several autoimmune or inflammatory diseases and humoral organ transplant rejection. De novo HHV\u20108 tumors induced by RTX used for these indications have not been reported previously. This study was undertaken to evaluate de novo HHV\u20108 tumors induced by RTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective study, we investigated the clinical, virologic, and pathologic features of 5 HIV\u2010negative male patients with HHV\u20108 tumors induced by RTX therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients were all immunocompromised by previous treatments, which consisted of steroids and\/or immunosuppressive agents, and received RTX for insufficient response, disease progression, or transplant rejection. They developed HHV\u20108 tumors a median of 4 months after beginning treatment with RTX (range 3\u201313 months). Four patients had at least 1 risk factor for HHV\u20108, including a high Fitzpatrick skin phototype (of &gt;3) (n\u00a0= 3) and homosexuality (n = 1). Four patients developed KS (all 4 had skin lesions and 2 had visceral involvement), and 1 patient developed a solid primary effusion lymphoma. RTX was discontinued in all patients, and immunosuppressants were reduced when feasible. After a median follow\u2010up of 20 months, 2 patients died. Remission of KS was complete in 1 patient and partial in 1 patient, and 1 patient had progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings indicate that patients who have a high skin phototype and are at risk of HHV\u20108 should be carefully screened for HHV\u20108 before RTX therapy. The safety of RTX, especially in nonlymphomatous disorders, should be carefully evaluated in patients at risk of HHV\u20108 tumors.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.40217","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T12:13:05Z","timestamp":1500379985000},"page":"2241-2246","source":"Crossref","is-referenced-by-count":11,"title":["Brief Report: De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in Autoimmune or Inflammatory Systemic Diseases"],"prefix":"10.1002","volume":"69","author":[{"given":"Amandine","family":"P\u00e9rier","sequence":"first","affiliation":[{"name":"Sorbonne University UPMC University of Paris 6 Unit\u00e9 fonctionnelle de Dermatologie Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP, Paris, France and M\u00e9decine Interne Centre Hospitalier Universitaire de Poitiers Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Savey","sequence":"additional","affiliation":[{"name":"Sorbonne University UPMC University of Paris 6 D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique National Center for Rare Autoimmune and Systemic Diseases and for Autoinflammatory Diseases AP\u2010HP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Sorbonne University UPMC University of Paris 6 Service de Virologie Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Serve","sequence":"additional","affiliation":[{"name":"Sorbonne University UPMC University of Paris 6 Service de Virologie Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[{"name":"Sorbonne University UPMC University of Paris 6 D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique National Center for Rare Autoimmune and Systemic Diseases and for Autoinflammatory Diseases AP\u2010HP INSERM UMR\u2010S 959 and D\u00e9partement Hospitalo\u2010Universitaire Inflammation\u2010Immunopathologie\u2010Biotherapie Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Barete","sequence":"additional","affiliation":[{"name":"Sorbonne University UPMC University of Paris 6 Unit\u00e9 fonctionnelle de Dermatologie Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP INSERM UMR\u2010S 959 and D\u00e9partement Hospitalo\u2010Universitaire Inflammation\u2010Immunopathologie\u2010Biotherapie Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7997879"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis1009"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3473"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0951"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376012"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.12.048"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0497-9"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2002.59000"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.9.3085"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.12.1452"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11601"},{"key":"e_1_2_6_14_1","first-page":"427","article-title":"Professional antigen presenting cells in human herpesvirus 8 infection","volume":"3","author":"Knowlton ER","year":"2012","journal-title":"Front Immunol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/v7010116"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150051"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.40217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:07:32Z","timestamp":1759939652000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.40217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1002\/art.40217"],"URL":"https:\/\/doi.org\/10.1002\/art.40217","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]}}}